ImmunoVaccine Technologies Partners with Scancell to Advance DNA Vaccine Delivery
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
ImmunoVaccine Technologies Inc. (IVT) has signed an agreement with UK-based Scancell Ltd., which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT's DepoVax™ delivery system for Scancell's novel ImmunoBody® DNA vaccines.
"Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration," remarked Dr. Marc Mansour, vice president of R D at IVT. "Our DepoVax™ technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques."
"IVT's DepoVax™ represents a potentially attractive future delivery system for our ImmunoBody® DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable." commented David Evans, chairman of Scancell.
DNA-based vaccines have gained popularity due to promising results reported the clinic, their relative ease of manufacture and potential for enhanced stability. There is currently a need for simple alternative methods of delivering DNA vaccines.
DepoVax™ is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax™ enhances the immunogenicity of antigens in general, and can be used to enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a contract manufacturing plant, making DepoVax™ amenable to commercialization.
"Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration," remarked Dr. Marc Mansour, vice president of R D at IVT. "Our DepoVax™ technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques."
"IVT's DepoVax™ represents a potentially attractive future delivery system for our ImmunoBody® DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable." commented David Evans, chairman of Scancell.
DNA-based vaccines have gained popularity due to promising results reported the clinic, their relative ease of manufacture and potential for enhanced stability. There is currently a need for simple alternative methods of delivering DNA vaccines.
DepoVax™ is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax™ enhances the immunogenicity of antigens in general, and can be used to enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a contract manufacturing plant, making DepoVax™ amenable to commercialization.
